Department of Internal Medicine, Naples Community Hospital, FL, USA.
J Investig Med High Impact Case Rep. 2024 Jan-Dec;12:23247096241262690. doi: 10.1177/23247096241262690.
Neuroleptic malignant syndrome (NMS) is a severe adverse reaction associated with neuroleptic or antipsychotic drugs. This case report discusses a 43-year-old man with a history of bipolar disorder and polysubstance abuse who presented with altered mental status, autonomic dysfunction, and muscular rigidity. The patient had recently started on ziprasidone, a second-generation antipsychotic, leading to an atypical presentation of NMS. Unlike classic findings associated with NMS induced by first-generation antipsychotics, this case lacked high fever, lead pipe rigidity, or elevated creatine kinase levels greater than 1000 on initial presentation. The delay in diagnosis was attributed to the milder symptoms and absence of typical findings, resulting in extensive diagnostic workup and interventions. The patient responded positively to treatment with lorazepam based on the Woodbury severity stage guidelines. This case underscores the complexity of diagnosing NMS induced by second-generation antipsychotics and highlights the need for awareness and tailored treatment approaches for atypical presentations.
神经阻滞剂恶性综合征(NMS)是一种与神经阻滞剂或抗精神病药物相关的严重不良反应。本病例报告讨论了一位 43 岁的男性,有双相情感障碍和多种物质滥用史,表现为精神状态改变、自主神经功能障碍和肌肉僵硬。该患者最近开始使用第二代抗精神病药齐拉西酮,导致出现非典型的 NMS 表现。与第一代抗精神病药引起的 NMS 的典型表现不同,该病例初始表现无高热、铅管样僵硬或肌酸激酶水平升高超过 1000。由于症状较轻且缺乏典型表现,导致进行了广泛的诊断性检查和干预,从而导致诊断延迟。根据 Woodbury 严重程度分级指南,患者对劳拉西泮治疗有良好反应。本病例强调了诊断第二代抗精神病药引起的 NMS 的复杂性,并强调了对非典型表现的认识和针对性治疗方法的必要性。